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Abstracts / Urological Science 27 (2016) S24eS35 S27cystitis and severe lower urinary tract symptoms (LUTS). We conducted an
in-depth epidemiological study to better understand the correlation be-
tween ketamine abuse and LUTS.
Materials and Methods: The survey was conducted in two private reha-
bilitation centers in Taiwan. Through self-administered questionnaires
(OABSS, IPSS, ICSI, ICPI and VAS), records of inmates, such as gender, age,
and details of using ketamine, including the way, amount, duration of
using ketamine as well as symptoms of urinary tract were obtained. Data
processing and statistical analysis were performed using statistical soft-
ware SPSS v.17. We analyzed all kinds of relative factors causing ketamine
cystitis and off factor, and established an occurrence and severity fore-
casting module.
Results: 106 ketamine abusers completed the questionnaires, including 11
women and 95 men. LUTS occurred after using ketamine for 24.67±26.36
(mean± SD) months. Most of them combined snoring and smoking of the
ketamine. Leading symptoms included frequency (67.3%), incomplete
voiding (66.3%) and nocturia (61.2%). The scores of OABSS, IPSS, ICSI, ICPI
and VAS were 5.23±4.37, 13.11±10.62, 11.47±6.78, 9.92±5.65, 2.89±3.48,
respectively. 79.2% of ketamine abusers admitted a history of poly-
substance abuse, although none of them had taken drugs other than ke-
tamine regularly. Smoking of ketamine was negatively correlated with
symptom scores in IPSS-S, ICSI and ICPI (P<0.05). OABSS signiﬁcantly
increased while combine using ketamine and Marijuana (P¼0.016). Com-
bination with 3,4-methylenedioxy-methamphetamine (MDMA) usage
signiﬁcantly increased the ICPI score (P¼0.034).
Conclusion: Ketamine abuse can induce severe storage symptoms
depending on the duration of using ketamine. Snorting of ketamine may
cause worsen LUTS than smoking. Combine using ketamine and certain
substances may exacerbate LUTS. With this model as a platform, further
prospective studies are warranted to investigate the appropriate choice of
treatment for this new clinical entity.
IPD12:
EVALUATION OF TREATMENT OUTCOMES IN PELVIC FLOOR MUSCLE
TRAINING WITH BIOFEEDBACK VERSUS INTRA-VAGINAL ELECTRICAL
STIMULATION IN WOMEN WITH URINARY INCONTINENCE IN HONG
KONG PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL
K.W. Yeung, K.L. Lui, W.F. Ho, C.M. Li, C.W. Fan, C.N. Tang.
Purpose: In Hong Kong, the prevalence of Female urinary incontinence is
around 35% and around 18% (~60,000 female) suffered from serve incon-
tinence. However, due to the fact that many women have poor coordina-
tion of pelvic ﬂoor muscle it leads to unsatisfactory treatment outcomes.
Few studies have compared the effectiveness of biofeedback pelvic ﬂoor
muscle training against intra-vaginal electrical stimulation in treating
urinary incontinence.
To evaluate the treatment outcomes and effectiveness of biofeedback
pelvic ﬂoor muscle training against intra-vaginal electrical stimulation for
female patients with urinary incontinence.
Materials and Methods: All patients who attended the female urinary
incontinence clinic from January 2014 to December 2015 were recruited
into the study and the outcomes were analyzed. All patients follow a
standard treatment protocol for the ﬁrst three months, they were taught
how to perform pelvic ﬂoor muscle training, life style modiﬁcation edu-
cation, etiology of urinary incontinence education and initial assessment
of symptom scores (UDI-6, IIQ7), no. of pad used and the time interval
between each micturition were documented. For those patients with poor
outcomes, patient would choose either using biofeedback pelvic ﬂoor
training or intra-vaginal stimulation for further three months. Symptom
scores were reassessed after therapy.
Results: During the study period, 1896 patients were recruited into the
study. Their ages were between 41e83 (mean 58.8). The average duration
of urinary incontinence (UI) was 4.5 years. Forty percent has mixed urinary
incontinence, 48% had stress incontinence and 12% had urge incontinence.
107 patients (5.6%) failed to show any signiﬁcant improvement despite
three months of initial treatment, of which 62 patients (57.9%) were then
proceeded to the intra-vaginal electrical stimulation group and 45 patients
(42.1%) to the biofeedback pelvic ﬂoor muscle-training group. After afurther 12 weeks of treatments, the intra-vaginal stimulation group, had
decreased UDI-6 of 1.4 (P<0.05) and IIQ7 decreased of 1.2 (P<0.05). The
biofeedback pelvic ﬂoor muscle training group had decreased UDI-6 of 2.2
(P<0.05) and IIQ7 of 2.3 (P<0.05). The no. of pad used per day reduced from
2.4 to 1.2(P<0.05) in intra-vaginal stimulation group; 2.3 to 2.1 (P< 0.05)
for the biofeedback pelvic ﬂoor muscle training group. The time interval
between each micturition increased from 1.4 hour to 2.8 hours (P< 0.05)
for both groups.
Conclusion: The results of this study showed that the intra-vaginal
stimulation and biofeedback were both equally effective for poor
responding patients. For the biofeedback group, the symptom scores and
quality of life scores showed better improvement comparing to the intra-
vaginal group. This may be because biofeedback is comparatively more
comfortable than intra-vaginal stimulation, not all patients accept intra-
vaginal probe insertion and for some patients with atrophic vagina,
introduction of probe may be painful. For the actual no. of pad used, the
intra-vaginal stimulation group showed a much more signiﬁcant
improvement. This may be accounted by the fact that direct stimulation
of pelvic ﬂoor muscle is useful for patients with poor active movement.
The drawback of this study is that the treatment options were patient
driven and not randomized but the advantage of patient driven treat-
ment is that patients are very compliance to time consuming rehabili-
tation program.
IPD13:
A CLINICAL NOMOGRAM FOR PREDICTING BLADDER OUTLET
OBSTRUCTION IN NON-NEUROGENIC MALE PATIENTS WITH
OVERACTIVE BLADDER
Wei-Jen Chen 1, Yu-Hua Fan 1,2,3, Alex T.L. Lin 1,2,3, Kuang-Kuo
Chen 1,2,3. 1Department of Urology, Taipei Veterans General Hospital, Taipei,
Taiwan; 2Department of Urology, School of Medicine, Taipei, Taiwan; 3 Shu-
Tien Urological Science Research Center, National Yang-Ming University,
Taipei, Taiwan
Purpose: Bladder outlet obstruction (BOO) is a common cause of over-
active bladder (OAB) symptoms in men, but not all men with OAB symp-
toms have BOO. The strategies for treatment of OAB symptoms are
different in men with BOO and those without BOO. Pressure-ﬂow studies
are considered the reference standard to diagnose BOO. However, the
procedure is invasive, expensive and time-consuming. A non-invasive
diagnostic method for BOO in men with OAB symptoms is warranted. The
nomogram creates a simple graphical representation of a statistically
predictive model which generates a numerical probability of a clinical
event. In this study, we want to develop a nomogram for detection of BOO
in male patients with OAB symptoms.
Materials and Methods: We prospectively recruited male patients pre-
senting with OAB symptoms from our urology outpatient clinic between
August 2008 and July 2015. Patients with overt neurological disorders
were excluded. All patients received the prostate speciﬁc antigen (PSA) test
and transabdominal ultrasound which provided the information of intra-
vesical prostatic protrusion (IPP), prostate volume (PV) and detrusor wall
thickness (DWT). Symptom severity was evaluated with International
Prostate Symptoms Score (IPSS), Overactive Bladder Symptom Score
(OABSS). All patients underwent catheter-free uroﬂowmetry, post-void
residual urine measurement and urodynamic pressure-ﬂow studies. BOO
was deﬁned based on a provisional ICS method for the deﬁnition of
obstruction, which deﬁned BOO as (PdetQmax-2Qmax) > 40. Multivariable
regression analysis was performed to assist in choosing candidate pre-
dictors to build up a nomogram. Internal validation of the nomogram was
performed.
Results: A total of 211 patients were enrolled. The mean age of the patients
was 73.6 years (range 52e91). BOO was diagnosed in 118 patients. Among
univariate analysis, patients with BOO had a higher prevalence of PSA>2
(p¼0.001), PV>30 (p¼0.003), longer IPP (p<0.001), and larger Qmax
(p<0.001), Qmean (p<0.001) on uroﬂowmetry. Among multivariate anal-
ysis, only IPP (p¼0.014) is statistically important, with odds ratio 3.119
(95% CI: 1.259e7.722). A nomogram, demonstrating a predictive accuracy
of 70%, was constructed from PSA, IPP and catheter-free Qmax.
Abstracts / Urological Science 27 (2016) S24eS35S28Conclusion: This nomogram is a predictive tool, upon external validation,
that can be used to counsel male patients with OAB symptoms in pre-
dicting the presence of BOO.
IPD14:
DIABETES MELLITUS PATIENTS REQUIRE HIGHER RATES OF
CONTINUING MEDICATION AFTER TRANSURETHRAL RESECTION OF
PROSTATE: IMPLICATIONS FROM TAIWAN NATIONWIDE POPULATION-
BASED COHORT STUDY
Chen-Pang Hou, Phei-Lang Chang, Chien-Lun Chen, Yu-Hsiang Lin, Pei-
Shan Yang, Ke-Hung Tsui. Department of Urology, Chang Gung Memorial
Hospital, Taoyuan, Taiwan
Purpose: The aim of this study was to compare the clinical outcomes
between diabetic patients and non-diabetic patients receiving transure-
thral resection of prostate (TUR-P).
Materials and Methods: This analysis was a retrospective cohort study
using 13 years (2000e2012) of claims data from Taiwan’s National Health
Insurance Research Database (NHIRD). A total of 4887 patients who had
persistent lower urinary tract symptoms (LUTS) and underwent TUR-P for
benign prostate hyperplasia (BPH) were enrolled and divided into two
groups: Diabetes mellitus (DM) group and Non-DM group. The patients’
characteristics, post-operative clinical outcomes, and the medication re-
cords after TUR-P were compared.
Results: Therewas no difference between the two groups in regards to age,
ratio of urinary tract infection (UTI) and urinary retention before surgery.
The pre-operative medication statuses were also similar between the two
groups. However, DM group patients had a higher prevalence of comor-
bidities. Post-operatively, the DM group had lower rates of UTI (OR, 0.78;
p¼0.009) and higher rates of urinary retention requiring catheterization
(OR, 1.35; p¼0.01) within 1 month after TUR-P. Both of the proportions
became insigniﬁcantly different during the 1 month to 1 year post-oper-
ative period. A higher proportion of patients with DM took anti-musca-
rinics (OR, 1.23; P ¼ 0.032) within the ﬁrst 3 months and a-blockers (OR,
1.18; P¼ 0.049) during 3e12months after receiving TUR-P. Overall, the DM
group patients had a worse post-operative medication-free survival
compared to that of non-DM group patients (95% CI¼1.14; p¼0.005).
Conclusion: Diabetes Mellitus patients require higher rates of continuing
medication after TUR-P, especially anti-muscarinics in three months post-
op and alpha-blocker after three months post-op. Diabetes Mellitus pa-
tients also had higher incidence of urine retention after surgery.
IPD15:
ONE-YEAR ANATOMIC OUTCOMES OF LAPAROSCOPIC SACROCOL-
POPEXY IN KAMEDA MEDICAL CENTER
Ting-Wen Huang, Jimmy Masayoshi Nomura, Shingo Moriyama, Shino
Tokiwa. Urogynecology Center, Kameda Medical Center, Japan
Purpose: For pelvic organ prolapse (POP) patients, voiding dysfunction is
associated with the increasing severity of cystocele. After surgical
correction of the prolapse, 89% patients had normalization of voiding
dysfunction (Fitzgerald MP, 2000). Prolapse repair surgery plays an
important role to resolve female lower urinary symptoms. Particularly,
laparoscopic sacrocolpopexy (LSC) provides the outcomes of the gold
standard abdominal approach while offering the beneﬁts of minimally
invasive surgery (Gabriel B, 2011). Since 2014, LSC became a new option for
POP patients covered by public health insurance in Japan. The aim of this
study is to clarify the postoperative anatomical change after LSC in Kameda
Medical Center.
Materials and Methods: We did a retrospective medical chart review
between April and December 2014 for patients who underwent LSC and
being followed up for one year in our center. The anatomical change was
assessed by using POP-Q. Recurrence rate and speciﬁc site were also
investigated.
Results: A total of 146 patients, aged 65.1±7.8, with average BMI 23.4±2.8,
were retrospectively enrolled. Average blood loss was 22.8±25.7ml with
238.5±45.3 minutes in operation time. For anatomical change assessed by
POP-Q, Aa changed from 1.1±1.4 to 2.9±0.3; Ba changed from 2.5±2. to
2.9±0.4; C changed from 1.4±3 to 7.4±1.4;gh changed from 4.4±1.1 to3.7±0.8; pb changed from 3.5±0.7 to 3.7±0.5; tvl changed from 8.1±1.1 to
8.6±1.2; Ap changed from 0±1.6 to 2.8±0.6; Bp changed from 0.6±2.4 to
2.7±0.7; D changed from 3.2±2.5 to 8.3±1.4. Aa, Ba, C, gh, tvl, Ap, Bp,
and D of POP-Q showed signiﬁcant differences between pre- and post-
operation. 8 patients (5.5%) showed recurrence during ﬁrst year after LSC.
2 patents were found to have recurrent anterior vaginal wall prolapse
while 7 patients had recurrent posterior wall prolapse. However, using
PFDI-20 to assess the feeling of a bulge for recurrent patients, no one felt a
bulge in the vaginal area.
Conclusion: POP patients receiving LSC showed signiﬁcant improvement
in anatomical outcome. Rate of recurrence in ﬁrst year after LSC was
about 5%.
IPD16:
EFFECTIVENESS OF NO-CGMP AXIS FOR LOWER URINARY TRACT
SYNDROME
Yukihide Matsui, Yurika Ito, Tomo Shimizu, Yota Nakajima, Toshihiro
Shimizu, Mizuki Kasahara, Koji Tamura, Toshihiro Tai, Masato
Nagata, Humito Yamabe, Kuri Aoki, Hideyuki Kobayashi, Koichi
Nagao, Koichi Nakajima. Department of Urology, Faculty of Medicine, Toho
University, Japan
Purpose: It is well known NO-cGMP axis plays a critical role in treatment
for erectile dysfunction. NO-cGMP axis is expected to not only ED but also
LUTS treatment due to regulate the smooth muscle relaxation. ZalutiaⓇ is
one of the PDE5 inhibitor launched in Japan on 2013 for LUTS treatment.
We evaluated the effectiveness of ZalutiaⓇ for LUTS and ED treatment.
Material and Methods: Between October 2014 and December 2015, 108
patients were prescribed ZalutiaⓇ 5mg per day in Toho University Medical
center Omori Hospital. Of 36patients were clinically evaluable such as PSA
level, prostate volume, IPSS (International prostate symptom score),
ﬂowmetry, EHS (erectile hardness score) and the diary of voiding.
Results: Effective rate for urinary symptoms, especially storage symptoms
including nocturia, daytime frequency and urgency, was 53% and for ED
was 76%. Medication discontinuance was noted 13 cases. 5 cases were due
to no effective, 2 were due to appearance of a new symptom and 6 were
due to side effect including hated erecting. Though there was no
improvement of the urinary symptom, 5 patients wanted to continue the
medication.
Conclusion: PDE5 inhibitor is safe and effective for LUTS treatment. PDE5
inhibitor gives an effect to erectile function supplementary and seems to




OPERATING TIMES AND CLINICAL OUTCOMES IN PERCUTANEOUS
NEPHROLITHOTOMY: A COMPARISON OF TRACT DILATION METHODS
Kuo-Kang Feng, Yuan-Ju Lee, I-Ni Chiang, Sho-Mon Wang, Kuo-How
Huang, Hong-Chiang Chang. Department of Urology, National Taiwan
University Hospital, College of Medicine, National Taiwan University, Taipei,
Taiwan
Purpose: The study investigated that two different tract dilatation method
affect operating times and bleeding complications associated with
percutaneous nephrolithotomy (PCNL) in the single-center study.
Materials and Methods: All patients who underwent PCNL for primary or
secondary treatment of kidney stone indications during the study period
(January, 2013 to August, 2015) were eligible for inclusion. PCNL pro-
cedures were performed according to local clinical guidelines and prac-
tices. Nephrostomy tract dilation was performed using balloon dilation or
Amplatz serial dilation. Hematologic complications assessed included
bleeding rates, transfusion rates, and preoperative and postoperative he-
moglobin values. Hospital stay (days) and the stone free rate are also
included into outcome parameters.
Results: The median operating time with balloon dilation (n ¼ 142) was
signiﬁcantly shorter than Amplatz serial dilation (n ¼54) at 88.0 vs 135.9
minutes, respectively (P < 0.0001). In the balloon dilation group, there was
